Budesonide/formoterol dry powder in asthma: an option for control as maintenance and reliever therapy

Bibliography

• Greening AP, Ind PW, Northfield M, Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994;344:219-24
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, Comparison of addition of salmeterol to invale steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 1996;153:1481-8
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Lofdahl CG, Postma DS, Effect of inhaled formoterol and budesonide on exacerbations of asthma: Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention – updated 2008. Available from: www.ginasthma.org [Last accessed 1 September 2009]
   Google Scholar
• Pauwels RA, Sears MR, Campbell M, Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial. Eur Respir J 2003;22:787-94
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Arvidsson P, Beckman O, Onset of bronchodilation of budesonide/formoterol versus salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001;14:29-34
   PubMed Web of Science ®Google Scholar
• Bateman ED, Boushey HA, Bousquet J, Can guideline defined asthma control be achieved? The Gaining Optimal Asthma Control study. Am J Respir Crit Care Med 2004;170:836-44
   PubMed Web of Science ®Google Scholar
• Nelson HS. Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma. J Allergy Clin Immunol 2001;107:398-416
   PubMed Web of Science ®Google Scholar
• Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma. Drugs 2000;60:1207-33
   PubMed Web of Science ®Google Scholar
• McGavin JK, Goa KL, Jarvis B. Inhaled budesonide/formoterol combination. Drugs 2001;61:71-8
   PubMed Web of Science ®Google Scholar
• Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ 2000;320:1368-73
   PubMed Web of Science ®Google Scholar
• Drury DE, Chong LK, Ghahramani P, Influence of receptor reserve on b-adrenoceptor-mediated responses in human lung mast cells. Br J Pharmacol 1998;124:711-18
   PubMed Web of Science ®Google Scholar
• Nials AT, Ball DI, Butchers PR, Formoterol on airway smooth muscle and human lung mast cells: a comparison with salbutamol and salmeterol. Eur J Pharmacol 1994;251:127-35
   PubMedGoogle Scholar
• Chong LK, Cooper E, Vardey CJ, Salmeterol inhibition of mediator release from human lung mast cells by b-adrenoceptor-dependent and independent mechanisms. Br J Pharmacol 1998;123:1009-15
   PubMedGoogle Scholar
• Connor BJ, Aikman SL, Barnes PJ. Tolerance to the non-bronchodilator effects of inhaled b2-agonists. N Engl J Med 1992;327:1204-8
   PubMed Web of Science ®Google Scholar
• Connor BJ, Fuller RW, Barnes PJ. Non-bronchodilator effects of inhaled b2-agonists. Am J Respir Crit Care Med 1994;150:381-7
   PubMedGoogle Scholar
• Erjefalt I, Persson CG. Long duration and high potency of antiexudative effects of formoterol in guinea-pig tracheobronchial airways. Am Rev Respir Dis 1991;144:788-91
   PubMedGoogle Scholar
• Bolton PB, Lefevre P, McDonald DM. Salmeterol reduces early- and late-phase plasma leakage and leukocyte adhesion in rat airways. Am J Respir Crit Care Med 1997;155:1428-35
   PubMed Web of Science ®Google Scholar
• Bowden JJ, Sulakvelidze I, McDonald DM. Inhibition of neutrophil and eosinophil adhesion to venules of rat trachea by b2-adrenergic agonist formoterol. J Appl Physiol 1994;77:397-405
   PubMed Web of Science ®Google Scholar
• Nichol G, Nix A, Barnes PJ, Prostaglandin F2a enhancement of capsaicin induced cough in man: modulation by b2-adrenergic and anticholinergic drugs. Thorax 1990;45:694-8
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scienti?c rationale for inhaled combination therapy with long-acting b2-agonists and corticosteroids. Eur Respir J 2002;19:182-91
   PubMed Web of Science ®Google Scholar
• Collins S, Caron MG, Lefkowitz RJ. b-adrenergic receptors in hamster smooth muscle cells are trans- criptionally regulated by glucocorticoids. J Biol Chem 1988;263:9067-70
   PubMed Web of Science ®Google Scholar
• Scott MG, Swan C, Wheatley AP, Identi?cation of novel polymorphisms within the promoter region of the human b2-adrenergic receptor gene. Br J Pharmacol 1999;126:841-44
   PubMed Web of Science ®Google Scholar
• Mak JCW, Nishikawa M, Barnes PJ. Glucocorticosteroids increase b2-adrenergic receptor transcription in human lung. Am J Physiol 1995;12:L41-6
   Google Scholar
• Mak JCW, Nishikawa M, Shirasaki H, Protective effects of a glucocorticoid on down-regulation of pulmonary b2-adrenergic receptors in vivo. J Clin Invest 1995;96:99-106
   PubMed Web of Science ®Google Scholar
• Nishikawa M, Mak JCW, Shirasaki H, Long term exposure to norepinephrine results in down-regulation and reduced mRNA expression of pulmonary b adrenergic receptors in guinea pigs. Am J Respir Cell Mol Biol 1994;10:91-9
   PubMedGoogle Scholar
• Nishikawa M, Mak JCW, Shirasaki H, Differential down-regulation of pulmonary b1- and b2-adrenoceptor messenger RNA with prolonged in vivo infusion of isoprenaline. Eur J Pharmacol (Molecular Section) 1993;247:131-8
   PubMed Web of Science ®Google Scholar
• Koto H, Mak JCW, Haddad E-B, Mechanisms of impaired b-adrenergic receptor relaxation by interleukin-1b in vivo in rat. J Clin Invest 1996;98:1780-7
   PubMed Web of Science ®Google Scholar
• Mak JCW, Hisada T, Salmon M, Reversal of IL-1b-induced up-regulation of G-protein-coupled receptor kinase activity by dexamethasone. Am J Respir Crit Care Med 2001;163:A228
   Google Scholar
• Adcock IM, Stevens DA, Barnes PJ. Interactions between steroids and b2-agonists. Eur Respir J 1996;9:160-8
   PubMed Web of Science ®Google Scholar
• Eickelberg O, Roth M, Lorx R, Ligand-independent activation of the glucocorticoid receptor by b2-adrenergic receptor agonists in primary human lung ?broblasts and vascular smooth muscle cells. J Biol Chem 1999;274:1005-10
   PubMed Web of Science ®Google Scholar
• McCormack PL, Lyseng-Williamson KA. Budesonide/formoterol. A review of its use as maintenance and reliever inhalation therapy in asthma. Drugs 2007;67:2407-31
   PubMedGoogle Scholar
• Brogden RN, McTavish D. Budesonide: an updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407
   PubMed Web of Science ®Google Scholar
• Barnes PJ. Scientific rationale for using a single inhaler for asthma control. Eur Respir J 2007;29:587-95
   PubMed Web of Science ®Google Scholar
• Hvizdos KM, Jarvis B. Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 2000;60:1141-78
   PubMed Web of Science ®Google Scholar
• Faulds D, Hollingshead LM, Goa KL. Formoterol: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991;42:115-37
   PubMed Web of Science ®Google Scholar
• Hospenthal MAC, Peters JI. Long-acting beta2-agonists in the management of asthma exacerbations. Curr Opin Pulm Med 2005;11:69-73
   PubMedGoogle Scholar
• Goldsmith DR, Keating GM. Budesonide/formoterol: a review of its use in asthma. Drugs 2004;64:1597-618
   PubMed Web of Science ®Google Scholar
• Cheer SM, Scott LJ. Formoterol: a review of its use in chronic obstructive pulmonarydisease. Am J Respir Med 2002;1:285-300
   PubMedGoogle Scholar
• Remington TL, DiGiovine B. Long-acting beta-agonists: anti-inflammatory properties and synergy with corticosteroids in asthma. Curr Opin Pulm Med 2005;11:74-8
   PubMed Web of Science ®Google Scholar
• Overbeek SE, Mulder PG, Baelemans SM, Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 2005;128:1121-7
   PubMedGoogle Scholar
• Haahtela T, Tamminen K, Malmberg LP, Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: a SOMA study. Eur Respir J 2006;28:748-55
   PubMed Web of Science ®Google Scholar
• Centenni S, Carlucci P, Santus P, Non-pulmonary effects induced the addition of formoterol to budesonide therapy in patients with mild or moderate persistent asthma. Respiration 2000;67:60-4
   PubMedGoogle Scholar
• Martin RJ, Szefler SJ, Chinchilli VM, Systemic effect comparisons of six inhaled corticosteroid preparations. Am J Respir Crit Care Med 2002;165:1377-83
   PubMed Web of Science ®Google Scholar
• Tronde A, Gillen M, Borgström L, Pharmacokinetics of budesonide and formoterol administered via 1 pressurized metered-dose inhaler in patients with asthma and COPD. J Clin Pharmacol 2008;48:1300-8
   PubMedGoogle Scholar
• Banov CH. The role of budesonide in adults and children with mild-to-moderate persistent asthma. J Asthma 2004;41:5-17
   PubMed Web of Science ®Google Scholar
• Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med 2000;343:1064-9
   PubMed Web of Science ®Google Scholar
• Källén B, Rydhstroem H, Aberg A. Congenital malformations after the use of inhaled budesonide in early pregnancy. Obstet Gynecol 1999;93:392-5
   PubMed Web of Science ®Google Scholar
• Ericson A, Källén B. Use of drugs during pregnancy: unique Swedish registration method that can be improved. Swed Med Prod Agency 1999;1:8-11
   Google Scholar
• Norjavaara E, Gerhardsson de Verdier M. Normal pregnancy out- comes in a population-based study including 2968 pregnant women exposed to budesonide. J Allergy Clin Immunol 2003;111:736-42
   PubMed Web of Science ®Google Scholar
• Berger WE. The use of inhaled formoterol in the treatment of asthma. Ann Allergy Asthma Immunol 2006;97:24-33
   PubMed Web of Science ®Google Scholar
• Lecaillon JB, Kaiser G, Palmisano M, Pharmacokinetics and tolerability of formoterol in healthy volunteers after a single high dose of foradil dry powder inhalation via aerolizer™. Eur J Clin Pharmacol 1999;55:131-8
   PubMed Web of Science ®Google Scholar
• Eklund A, Tronde A, Hellberg IJ, Pharmacokinetics of budesonide and formoterol administered via a series of single-drug and combination inhalers: four open-label, randomized, crossover studies in healthy adults. Biopharm Drug Dispos 2008;29:382-95
   PubMedGoogle Scholar
• AstraZeneca UK Limited. Symbicort® 200/6 Turbohaler®: summary of product characteristics. Available from: http://emc.medicines.org.uk [Last accessed 1 September 2009]
   Google Scholar
• Cazzola M, Santus P, Di Marco F, Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPD. Pulm Pharmacol Ther 2004;17:121-5
   PubMed Web of Science ®Google Scholar
• BTS/SIGN. National guidelines on management of asthma. Thorax 2003;58(Suppl 1):i1-i83
   Google Scholar
• Bousquet J, Boulet LP, Peters MJ, Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 2007;101:2437-46
   PubMed Web of Science ®Google Scholar
• Kuna P, Peters MJ, Manjra AI, Effect budesonide/formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007;61:725-36
   PubMed Web of Science ®Google Scholar
• O'Byrne PM, Bisgaard H, Godard PP, Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005;171:129-36
   PubMed Web of Science ®Google Scholar
• Rabe KF, Atienza T, Magyar P, Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006;368:744-53
   PubMed Web of Science ®Google Scholar
• Vogelmeier C, D'Urzo A, Pauwels R, Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005;26:819-28
   PubMed Web of Science ®Google Scholar
• Pavord ID, Jeffery PK, Qui Y, Airway in?ammation in patients with asthma with high-?xed or low-?xed plus as-needed budesonide/formoterol. J Allergy Clin Immunol 2009;123:1083-9
   PubMed Web of Science ®Google Scholar
• Sears MR, Boulet LP, Laviolette M, Budesonide/formoterol maintenance and reliever therapy: impact on air way inflammation in asthma. Eur Respir J 2008;31:982-9
   PubMed Web of Science ®Google Scholar
• Wang K, Liu CT, Wu YH, Budesonide/formoterol decreases expression of vascular endothelial growth factor (VEGF) and VEGF receptor 1 within air way remodelling in asthma. Adv Ther 2008;25:342-54
   PubMed Web of Science ®Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, The salmeterol multicenter asthma research trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129:15-26
   PubMed Web of Science ®Google Scholar
• Humbert M, Andersson TLG, Buhl R. Budesonide and formoterol for maintenance and reliever therapy in the management of moderate to severe asthma. Allergy 2008;63:1567-80
   PubMed Web of Science ®Google Scholar
• Rabe KF, Pizzichini E, Stallberg B, Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma. A randomized, double-blind trial. Chest 2006;129:246-56
   PubMed Web of Science ®Google Scholar
• Suissa S, Dell'Aniello S, Ernst P. Effectiveness of combination therapy in asthma: an observational study. Pulm Pharnmacol Ther 2009;22:194-98
   PubMedGoogle Scholar
• Price D, Wirén A, Kuna P. Cost-effectiveness of budesonide/formoterol for maintenance and reliever asthma therapy. Allergy 2007;62:1189-98
   PubMed Web of Science ®Google Scholar
• Hussain S. Way forward is not obvious at asthma crossroads. BMJ . 2007;335:577
   PubMedGoogle Scholar
• Demoly P, Louis R, Søes-Petersen U, Budesonide/formoterol maintenance and reliever therapy versus conventional best practice. Respir Med 2009;103:1623-32
   PubMed Web of Science ®Google Scholar
• The Cochrane Library. Available from: www3.interscience.wilwy.com/cgi-bin/mrwhome/106568753/HOME
   Google Scholar
• Lasserson TJ, Cates CJ, Ferrara G, Combination fluticasone and salmeterol versus ?xed dose combination budesonide and formoterol for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;1:CD004106, doi: 10.1002/14651858.CD004106.pub3
   Google Scholar
• Cates CJ, Lasserson TJ. Combination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and children. Cochrane Database Syst Rev 2009;1:CD007085, doi: 10.1002/14651858.CD007085.pub2
   Google Scholar
• Cates CJ, Lasserson TJ. Combination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 2009;2:CD007313, doi: 10.1002/14651858.CD007313.pub2
   Google Scholar
• O'Byrne. How much is too much? The treatment of mild asthma. Eur Respir J 2007;30:403-6
   PubMed Web of Science ®Google Scholar
• Adcock IM, Caramori G, Chung KF. New targets for drug development in asthma. Lancet 2008;372:1073-87
   PubMed Web of Science ®Google Scholar
• Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006;368:804-13
   PubMed Web of Science ®Google Scholar
• Anderson GP. Endotyping asthma: new insights into key pathogenic mechanisms in a complex, heterogeneus disease. Lancet 2008;372:1107-19
   PubMed Web of Science ®Google Scholar